A New Potential Contrast Agent for Magnetic Resonance Imaging: Iron Oxide-4A Nanocomposite.
Contrast Agent
Iron Oxide
Nanocomposite
Relaxivity
Magnetic Resonance Imaging
Journal
Journal of biomedical physics & engineering
ISSN: 2251-7200
Titre abrégé: J Biomed Phys Eng
Pays: Iran
ID NLM: 101589641
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
08
04
2017
accepted:
14
10
2017
entrez:
20
6
2019
pubmed:
20
6
2019
medline:
20
6
2019
Statut:
epublish
Résumé
Magnetic resonance imaging (MRI) contrast agents have an important role to differentiate healthy and diseased tissues. Access and design new contrast agents for the optimal use of MRI are necessary. This study aims to evaluate iron oxide-4A nanocomposite ability to act as a magnetic resonance imaging contrast agent. Iron oxide-4A nanocomposite (F4A) was synthesized. MTT assay was used to consider the nanocomposite safety for cell culture. The T1 and T2 relaxation times were measured using a 1.5 Tesla clinical MRI scanner. Then the corresponding relaxivities were determined. The average particle diameter of the nanocomposite was 50 to 100 nm based on scanning electron microscope (SEM) image. A linear relationship between relaxation rates and the Fe concentration of the nanocomposite was obtained. The T1 and T2 relaxivities of the nanocomposite were calculated 5.413 and 1092.1 mM The high T2/T1 relaxivity ratio of the iron oxide-4A nanocomposite confirms it's potential to act as a T2 contrast agent.
Sections du résumé
BACKGROUND
BACKGROUND
Magnetic resonance imaging (MRI) contrast agents have an important role to differentiate healthy and diseased tissues. Access and design new contrast agents for the optimal use of MRI are necessary. This study aims to evaluate iron oxide-4A nanocomposite ability to act as a magnetic resonance imaging contrast agent.
MATERIAL AND METHODS
METHODS
Iron oxide-4A nanocomposite (F4A) was synthesized. MTT assay was used to consider the nanocomposite safety for cell culture. The T1 and T2 relaxation times were measured using a 1.5 Tesla clinical MRI scanner. Then the corresponding relaxivities were determined.
RESULTS
RESULTS
The average particle diameter of the nanocomposite was 50 to 100 nm based on scanning electron microscope (SEM) image. A linear relationship between relaxation rates and the Fe concentration of the nanocomposite was obtained. The T1 and T2 relaxivities of the nanocomposite were calculated 5.413 and 1092.1 mM
CONCLUSION
CONCLUSIONS
The high T2/T1 relaxivity ratio of the iron oxide-4A nanocomposite confirms it's potential to act as a T2 contrast agent.
Types de publication
Journal Article
Langues
eng
Pagination
211-216Références
Mater Sci Eng C Mater Biol Appl. 2016 Sep 1;66:251-258
pubmed: 27207061
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1471-504
pubmed: 17116343
J Mater Chem B. 2015 Aug 14;3(30):6261-6273
pubmed: 32262745
Int J Mol Med. 2016 Nov;38(5):1319-1326
pubmed: 27666161
Int J Pharm. 2007 Mar 1;331(2):197-203
pubmed: 17141984
Mater Sci Eng C Mater Biol Appl. 2014 Aug 1;41:161-7
pubmed: 24907749
NMR Biomed. 2004 Nov;17(7):484-99
pubmed: 15526347
Inorg Chem. 2007 Jul 23;46(15):6190-6
pubmed: 17589991
J Magn Reson Imaging. 1995 Sep-Oct;5(5):499-508
pubmed: 8574032
Toxicol Rep. 2014 Nov 07;2:27-39
pubmed: 28962334
Small. 2014 Oct 15;10(19):3962-9
pubmed: 25044378
Quant Imaging Med Surg. 2011 Dec;1(1):35-40
pubmed: 23256052
Nanomedicine. 2012 Apr;8(3):275-90
pubmed: 21930108